CME Presentations

Gastric Cancer



  • Manish A. Shah, MD, FASCO

    Manish A. Shah, MD, FASCO

    Manish A. Shah, MD, FASCO

    Professor of Medicine

    Manish A. Shah, MD, FASCO is professor of medicine at Weill Medical College of Cornell University, where he also serves as the Bartlett Family professor for gastrointestinal malignancies, chief of the Solid Tumor Service, and director of the Gastrointestinal Oncology Program in the Division of Hematology and Medical Oncology. Dr. Shah is the current chair for the American Society of Clinical Oncology (ASCO) Clinical Delivery Care Council and previous chair of the ASCO Clinical Practice Guideline Committee. His career is focused on the care of patients with gastrointestinal malignancies through improved care delivery, drug development, and defining of disease subtypes.
  • Zev Wainberg, MD

    Zev Wainberg, MD

    Zev Wainberg, MD

    Professor of Medicine and Surgery Co-Director

    Zev Wainberg, MD is an academic medical oncologist specializing in gastrointestinal malignancies at the David Geffen UCLA School of Medicine. He is the co-director of the Gastro-Intestinal Oncology Program and medical director of the Pancreas Cancer Center at UCLA, with a joint appointment in medicine and surgery. Dr. Wainberg is also director of the Early Phase Clinical Research Program at the Jonsson Comprehensive Cancer Center at UCLA. He is the principal investigator on more than 25 clinical trials focused on targeted therapeutics in patients with gastrointestinal cancers.

CME Information

Global Logo PQH Logo

The Dawn of New Treatment Approaches for HER2-negative Advanced Unresectable or Metastatic Gastric or GEJ Cancers

Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.


This activity is supported by independent medical educational grants from Astellas and Merck.


This activity was released on November 9, 2023 and is valid until November 9, 2024. Requests for credit must be made no later than November 9, 2024.


The primary target audience for this activity are medical oncologists, GI oncologists, gastroenterologists, oncology nurses, nurse practitioners, physician assistants, oncology pharmacists, and other clinicians involved in the management of patients with gastric or GEJ cancer.


Gastric and gastroesophageal junction (GEJ) cancers are difficult to treat and have poor prognosis, particularly for patients who do not carry HER2 alterations. Recent advances in targeted therapy and immunotherapy for HER2-negative advanced gastric and GEJ cancers are changing the treatment landscape for these difficult-to-treat cancers, providing new treatment options and improving patient outcomes.

Join a panel of two gastrointestinal oncologists to discuss novel biomarkers that can guide treatment of HER2-negative gastric cancer, factors that can influence therapy selection for patients, and strategies to maximize outcomes by managing treatment-associated adverse events.


After completing this activity, the participant should be better able to:
  • Discuss biomarker testing and its significance in selecting therapy to manage patients with gastric and GEJ cancers
  • Evaluate efficacy and safety data from practice-changing clinical trials on new and emerging targeted therapies for HER2-negative metastatic gastric and GEJ cancers
  • Discuss optimum management of MSI-H/dMMR tumors with immune checkpoint inhibitors (ICIs)
  • Outline adverse events associated with targeted therapies and immunotherapies for HER2-negative metastatic gastric and GEJ cancers



In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Conflicts of Interest
Manish A. Shah, MD, FASCO
Chief, Solid Tumor Oncology Service
Director, Gastrointestinal Oncology Program
Co-Director, Center for Advanced Digestive Care
Bartlett Family Professor of Gastrointestinal Oncology
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
Research Grant: Astellas, Bristol Meyers Squibb, Merck
Zev Wainberg, MD
Professor of Medicine and Surgery
Co-Director, GI Oncology Program
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Consultant, Advisor: Amgen, Arcus, Astellas, Astra Zeneca, Bayer, Bristol Meyers Squibb, Daiichi, Gilead, Ipsen, Merck, Novartis, Seagen
Grant: Arcus, Bristol Meyers Squibb

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:

For additional information about the accreditation of this activity, please visit

Technical Support:

For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at